Multimodality Cardiac Imaging for Disease Progression in ATTR-CM

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
AgeNot listed
SponsorDominik Benz

About this trial

The goal of this clinical trial is to investigate whether new imaging techniques can help us to better understand the cardiac amyloidosis. The disease can be slowed down with various medications (e.g., tafamidis, acoramidis, or vutrisiran). However, treatment is not effective in all patients-in about one-third of cases, the disease continues to progress. So far, we know little about the exact causes of this and what biological changes occur in the heart muscle.

The main question it aims to answer is:

Will new imaging techniques help us understand the course of the cardiac amyloidosis?

Participants will have additional examinations:

* At the beginning of the study: one additional heart ultrasound examination, one cardiac MRI and one cardiac PET, blood examination during the regular examination, questionnaires. * After a year: one additional heart ultrasound examination, one cardiac MRI and one cardiac PET, blood examination during the regular examination.

Time required:

* Heart ultrasound examination: 5-10 Minutes * Cardiac MRI: 2 hours * Cardiac PET: 2 hours * Questionnaires: 5-10 Minutes.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Participants with cardiac ATTR amyloidosis, as recently defined by multi-societal criteria, who are about to start tafamidis at the University Hospital Zurich

Disqualifiers

Any other disease-modifying therapy (e.g. patisiran)

Ongoing supraventricular arrhythmia

Ventricular pacing

Prior septal myocardial infarction

Trial design

Design model

Single group

Treatments tested in this trial

  • FAPI tracer

    Diagnostic test

    18F-FAPI-74 PET/CT, cardiac MRI, echocardiography and blood sample for BMP5 serum concetration is performed at baseline and 12-month follow-up.

Treatment groups

50 Participants
are divided into 1 treatment group
Group A: 18F-FAPI PET/CTExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Change in FAPI uptake

F-FAPI-74 PET/CT is performed at baseline and 12-month follow-up. Images are acquired on a PET/CT scanner 60 minutes after intravenous injection of F-FAPI-74. The emission scan is obtained from the apex of the lung to the base of the lung. One bed position is acquired (20 minutes, 3-dimensional mode), and the heart is set at the center of the view. Myocardial F-FAPI-74 uptake is quantified by the mean standardized uptakte value of the LV volume of interest (VOI). The epicardial LV contour is drawn on the CT scan and, to correct for blood pool activity, the endocardial border is defined automatically by thresholding for 2 times the mean SUV of the blood pool.

Time frame
Baseline and 1 year

Secondary outcomes

1

Change in echocardiographic myocardial stiffness

Cardiac intrinsic elastography from echocardiography is performed at baseline and at 12-month follow-up. Ultrahigh-frame rate tissue Doppler data (\>250 frames/sec) are acquired using clinical scanners from the apical fourchamber view while carefully aligning the septal wall with the Doppler beam. The base-to-apex propagation of the late diastolic myocardial stretch wave can be visualized with ultrafast imaging data. The slope of the isovelocity wave front, called intrinsic velocity propagation (iVP) of myocardial stretch (in meters per second) is measured offline. By averaging values for three cardiac cycles, a global value is generated.

Time frame
Baseline and 1 year
2

Change in extracellular volume (ECV)

Cardiac MRI is performed at baseline and 12-month follow-up. Myocardial LV native T1 maps are acquired in 3 short-axis slices at the base, mid and apical levels using the modified Look-Locker inversion (MOLLI) recovery technique at end-diastole for 3 cycles (5-3-1 R-R durations with 3-4 R-R rest periods) during a single breath hold. T1 mapping is repeated with the same settings 10 minutes after intravenous administration of 0.1 mmol/kg of gadolinium contrast agent. The ECV fraction is estimated by plotting the reciprocal of each segmental myocardial T1 against the reciprocal of the blood pool T1 for native, 10-minute post-contrast MOLLI acquisitions, then calculating linear regression slopes, corresponding to segmental partition coefficients for gadolinium (λGd). Each λGd was multiplied by (1 - hematocrit) to obtain ECV fractions.

Time frame
Baseline and 1 year
3

Change in BMP4 expression and serum concentration

Serum samples are analyzed. BMP4 levels in the samples were measured using a human BMP4 SimpleStep ELISA Kit following manufacturer's instructions. Endomyocardial biopsies as part of the clinical diagnostic routine from the subgroup of 10 participants with suspicion of cardiac ATTR amyloidosis are analyzed. Cardiac tissue is fixed in 4% formaladehyde and embedded in paraffin. Histopathological changes are evaluated after H\&E staining and the area of percentage of collagen networks per section is determined. For the assessment of BMP4 mRNA expression in tissue, homogenates are generated, samples are centrifuged and the supernatant is used for ELISA measurements.

Time frame
Baseline and 1 year

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Dominik Benz

Lead sponsor

University of Zurich

Sponsor institution

Olga Mayenfisch Stiftung, Zurich, Switzerland

Collaborator

University of Zurich

Collaborator